

The area described aggregates 32,734 acres, more or less, of which about 21,270 acres are classified as coal lands, and about 11,464 acres are classified as non-coal lands.

ARTHUR A. BAKER,
Acting Director.

APRIL 29, 1966.

[F.R. Doc. 66-4949; Filed, May 5, 1966;
8:46 a.m.]

**Office of the Secretary
HOLLYWOOD INDIAN
RESERVATION**

Designation

Pursuant to Resolution No. C-23-66 of the Tribal Council of the Seminole Tribe of Florida, adopted January 14, 1966, and the petition of the Chairman of the Tribal Council in accordance therewith, and after finding that the same is in the public interest and in the interest of the Indians affected thereby, notice is hereby given that that part of the reservation for the Seminole Indians in southern Florida, sometimes known as the Broward County Reservation or as the Dania Reservation (Act of Oct. 4, 1961, 75 Stat. 804, amending the Act of Aug. 9, 1955, 69 Stat. 539, as amended, 25 U.S.C. sec. 415 (1964)), is hereby designated and shall for all purposes be known as the Hollywood Indian Reservation.

STEWART L. UDALL,
Secretary of the Interior.

MAY 2, 1966.

[F.R. Doc. 66-4953; Filed, May 5, 1966;
8:47 a.m.]

DEPARTMENT OF COMMERCE

Maritime Administration

AMERICAN PRESIDENT LINES, LTD.

Notice of Application

Notice is hereby given that American President Lines, Ltd., seeks to provide service between Hawaii and the Far East on up to 26 voyages per annum with ships operating on its transpacific freight service on trade route No. 29. The company presently is authorized to make up to 37 sailings on its transpacific freight service between California and the Far East, but ships operating on this service are not authorized to call at Hawaii. The company's application to provide service in the domestic trade between California and Hawaii is presently the subject of Docket S-191. The company's requests would enable it to make annually up to 26 calls at Hawaii in each direction with freight ships operating on its transpacific freight service.

Any person, firm or corporation having any interest in such application and desiring a hearing on issues pertinent to section 605(c) of the Merchant Marine Act, 1936, as amended, 46 U.S.C. 1175, should by the close of business on May 20, 1966, notify the Secretary, Maritime Subsidy Board in writing, in tripli-

cate, and file petition for leave to intervene in accordance with the rules of practice and procedure of the Maritime Subsidy Board.

In the event a hearing is ordered to be held on the application under section 605(c), the purpose thereof will be to receive evidence relevant to (1) whether the application is one with respect to a vessel to be operated on a service, route or line served by citizens of the United States which would be in addition to the existing service, or services, and, if so, whether the service already provided by vessels of U.S. registry in such service, route or line is inadequate, and (2) whether in the accomplishment of the purposes and policy of the act additional vessels should be operated thereon.

If no request for hearing and petition for leave to intervene is received within the specified time, or if the Maritime Subsidy Board determines that petitions to intervene filed within the specified time do not demonstrate sufficient interest to warrant a hearing, the Maritime Subsidy Board will take such action as may be deemed appropriate.

Dated: May 3, 1966.

By order of the Maritime Subsidy Board.

JAMES S. DAWSON, JR.,
Secretary.

[F.R. Doc. 66-4988; Filed, May 5, 1966;
8:50 a.m.]

**DEPARTMENT OF HEALTH, EDU-
CATION, AND WELFARE**

Food and Drug Administration

[Docket No. FDC-D-92; NDA No. 13-416]

RIKER LABORATORIES, INC.

**Norgesic Tablets; Notice of
Opportunity for Hearing**

Notice is hereby given to Riker Laboratories, Inc., Northridge, Calif., that the Commissioner of Food and Drugs proposes to issue an order, under the provisions of section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)), withdrawing approval of new-drug application No. 13-416 and all amendments and supplements thereto held by Riker Laboratories, Inc., for the drug "Norgesic Tablets (orphenadrine citrate, 25 milligrams; aspirin, 225 milligrams; phenacetin, 160 milligrams; caffeine, 30 milligrams)," on the ground that:

1. New information before the Food and Drug Administration with respect to such drug, evaluated together with the evidence available when the application was approved, show that there is a lack of substantial evidence that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling thereof, in that: New evidence concerning two clinical investigations of Norgesic Tablets reported by Cass Research Associates, Inc., Cam-

bridge, Mass., conducted under the sponsorship of and submitted by the applicant as evidence in said application of the effectiveness of the drug, and which were pertinent to the approval of said new-drug application, shows the presence of irregularities in the reports of these investigations such that the studies are not adequate as a basis on which it can fairly and responsibly be concluded by experts, qualified by scientific training and experience to evaluate the effectiveness of the drug involved, that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its labeling.

2. The new-drug application contains untrue statements of material fact. Specifically, two clinical investigations reported by Cass Research Associates, Inc., identified by Project Code No. 62-12-A dated January 28, 1963, and Project Code No. 63-5-B dated September 3, 1963, and submitted by the applicant in said application as evidence of the effectiveness of Norgesic Tablets, contain untrue statements of material fact in that:

a. They contain the identification of a number of persons reported as being treated with the drug during the period of said investigations who in fact were not so treated. During all or part of the time pertinent to these investigations a significant number of these persons were not hospitalized at the institution where the investigations were allegedly conducted, as stated in the application. Some of the persons reported as being treated were actually deceased.

b. They contain the identification of clinical conditions for which a number of persons were being treated with the drug, which conditions are contrary to the records of the institution where the investigations were allegedly conducted.

c. They omit full information concerning other relevant treatments, evidenced by the records of the institution where the investigations were allegedly conducted, given concurrently to patients reportedly being treated with the subject drug.

d. They omit full information on all clinical conditions of the persons reported as being treated with the drug during these investigations.

e. They contain statements of adverse effects and useful results observed in a number of persons being treated with the drug, which observations for reasons specified in paragraphs a, b, c, and d above could not have been made.

In accordance with the provisions of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) and the regulations appearing in Title 21, Code of Federal Regulations, Part 130, the Commissioner will give the applicant, and any interested person who would be adversely affected by an order withdrawing such approval, an opportunity for a hearing, at which time such persons may produce evidence and arguments to show why approval of new-drug application No. 13-416 should not be withdrawn.

Within 30 days from the date of publication of this notice in the FEDERAL

REGISTER, such persons are required to file with the Hearing Clerk of the Department of Health, Education, and Welfare, Office of the General Counsel, Food and Drug Division, Room 5440, 330 Independence Avenue SW., Washington, D.C., 20201, a written appearance electing whether:

1. To avail themselves of the opportunity for a hearing; or
2. Not to avail themselves of the opportunity for a hearing.

If such persons elect not to avail themselves of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing the approval of the new-drug application.

Failure of such persons to file such a written appearance of election within 30 days following the date of publication of this notice in the FEDERAL REGISTER will be construed as an election by such persons not to avail themselves of the opportunity for a hearing.

The hearing contemplated by this notice will be open to the public, except that any portion of the hearing that concerns a method or process which the Commissioner finds is entitled to protection as a trade secret will not be open to the public, unless the respondent specifies otherwise in his appearance.

If such persons elect to avail themselves of the opportunity for a hearing by filing a timely written appearance of election, a hearing examiner will be named by the Commissioner and he shall issue a written notice of the time and place for the hearing.

This notice is issued under the authority contained in the Federal Food, Drug, and Cosmetic Act (secs. 505, 701(a), 52 Stat. 1052, as amended, 1055; 21 U.S.C. 355, 371(a)), and delegated to the Commissioner by the Secretary of Health, Education, and Welfare (21 CFR 2.120; 31 F.R. 3008).

Dated: April 28, 1966.

JAMES L. GODDARD,
Commissioner of Food and Drugs.

[F.R. Doc. 66-4939; Filed, May 5, 1966;
8:45 a.m.]

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of the Secretary

ASSISTANT SECRETARY FOR METRO- POLITAN DEVELOPMENT

Delegation of Authority Regarding Grants for Water and Sewer Facilities

The Assistant Secretary for Metropolitan Development is hereby authorized:

1. To execute the powers and functions vested in the Secretary of Housing and Urban Development under sections 702 and 705 of the Housing and Urban Development Act of 1965 (42 U.S.C. 3102 and 3105) with respect to grants for water and sewer facilities except the authority to sue and be sued pursuant to

section 705(a) of the said 1965 Act and section 402(c) (3) of the Housing Act of 1950, as amended (12 U.S.C. 1749a(c) (3)).

2. To redelegate to one or more employees under his jurisdiction and to each Regional Administrator any of the authority delegated herein, and to authorize redelegation by the Regional Administrator.

(Secs. 702 and 705, 79 Stat. 490 and 492, 42 U.S.C. 3102 and 3105; sec. 5(a), 79 Stat. 669, 5 U.S.C. 624c(a); sec. 7(d), 79 Stat. 670, 5 U.S.C. 624d(d))

Effective date. This delegation of authority shall be effective as of May 6, 1966.

ROBERT C. WEAVER,
Secretary of Housing and
Urban Development.

[F.R. Doc. 66-4976; Filed, May 5, 1966;
8:49 a.m.]

REGIONAL ADMINISTRATORS

Redelegation of Authority Regarding Grants for Water and Sewer Facilities

Each Regional Administrator in the Department of Housing and Urban Development in carrying out the program of grants for water and sewer facilities under sections 702 and 705 of the Housing and Urban Development Act of 1965 (42 U.S.C. 3102 and 3105) is hereby authorized:

1. To approve applications, authorize grants, and execute grant agreements, involving grants for water and/or sewer facilities.

-2. To amend or modify any such grant agreement.

3. To redelegate to one or more employees under his jurisdiction the authority delegated herein except the authority to approve applications, authorize grants, and amend or modify the terms thereof.

4. In the case of the Regional Administrator, Region VI (San Francisco), to redelegate to the Director for Northwest Operations, Region VI, at Seattle, Wash., any of the authority redelegated herein.

(Secretary's delegation effective May 6, 1966, 31 F.R. 6796)

Effective date. This redelegation of authority shall be effective as of May 6, 1966.

CHARLES M. HAAR,
Assistant Secretary for
Metropolitan Development.

[F.R. Doc. 66-4977; Filed, May 5, 1966;
8:49 a.m.]

ATOMIC ENERGY COMMISSION

[Docket No. 50-34]

WESTINGHOUSE ELECTRIC CORP.

Notice of Issuance of Facility License Amendment

Please take notice that the Atomic Energy Commission has issued, effective as of the date of issuance, Amend-

ment No. 14, set forth below, to Facility License No. CX-6. The license authorizes Westinghouse Electric Corp. to operate the Critical Reactor Experiment (CRX) Facility located at the Westinghouse Reactor Evaluation Center near Waltz Mill in Westmoreland County, Pa. The amendment revises the license in its entirety and incorporates technical specifications in the license in accordance with the application for license amendment dated March 1, 1965.

Within 15 days from the date of publication of this notice in the FEDERAL REGISTER, the licensee may file a request for a hearing, and any person whose interest may be affected by this proceeding may file a petition for leave to intervene. Requests for a hearing and petitions to intervene shall be filed in accordance with the provisions of the Commission's rules of practice, 10 CFR Part 2. If a request for a hearing or a petition for leave to intervene is filed within the time prescribed in this notice, the Commission will issue a notice of hearing or an appropriate order.

For further details with respect to this amendment, see (1) the application for license amendment and (2) a related safety evaluation prepared by the Research and Power Reactor Safety Branch of the Division of Reactor Licensing, both of which are available for public inspection at the Commission's Public Document Room, 1717 H Street NW., Washington, D.C. A copy of item (2) above may be obtained at the Commission's public document room, or upon request addressed to the Atomic Energy Commission, Washington, D.C., 20545, Attention: Director, Division of Reactor Licensing.

Dated at Bethesda, Md., this 29th day of April 1966.

For the Atomic Energy Commission.

R. L. DOAN,
Director,
Division of Reactor Licensing.

FACILITY LICENSE AMENDMENT

[License No. CX-6; Amdt. 14]

The Atomic Energy Commission having found that:

a. The application for license amendment, dated March 1, 1965, complies with the requirements of the Atomic Energy Act of 1954, as amended, and the Commission's regulations set forth in Title 10, Chapter I, CFR;

b. There is reasonable assurance that (1) the activities authorized by this license, as amended, can be conducted at the designated location without endangering the health and safety of the public, and (2) such activities will be conducted in compliance with the rules and regulations of the Commission;

c. Westinghouse Electric Corp. is technically and financially qualified to engage in the activities authorized by this license, as amended, in accordance with the rules and regulations of the Commission;

d. Westinghouse Electric Corp. has furnished proof of financial protection to satisfy the requirements of 10 CFR Part 140;

e. The issuance of this license amendment will not be inimical to the common defense and security or to the health and safety of the public; and

f. Prior public notice of proposed issuance of this amendment is not required since the